

IMPORTANT CONFIDENTIALITY NOTICE

The documents accompanying this telecopy transmission contain confidential information belonging to the sender which is legally protected. The information is intended only for the use of the individual or entity named below. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this telecopied information is strictly prohibited. If you have received this telecopy in error, please immediately notify us by telephone (collect) to arrange for return of the telecopied document to us.

TO: United States Patent and Trademark Office

Fax No. 571-273-8300

FROM: Mary E. Yauger

Fax No. 513-634-3752

Phone No. 513-634-4223

Application No.: 10/792,149

Inventor(s):

Scarchilli et al

Filed:

3/3/2004

Docket No.:

9173L

Confirmation No.: 4849

FACSIMILE TRANSMITTAL SHEET AND

CERTIFICATE OF TRANSMISSION UNDER 37 C.F.R. §1.8

Listed below are the item(s) being submitted with this Certificate of Transmission:**

1) Response to Restriction Requirement (Page 8)

Number of Pages Including this Page: 9

Comments:

**Note: Each paper must have its own certificate of transmission, OR this certificate must identify each submitted paper.

(FAX-USPTO.doc Revised 11/18/2005)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No. : 10/792,149 GENTRAL

JUL 2 8 2006

Applicant(s) :

John Joseph Scarchilli

Filed

March 3, 2004

Title

LIQUID INFUSION PODS CONTAINING

INSOLUBLE MATERIALS

TC/A.U.

Examiner

Reginald Alexander

Conf. No.
Docket No.
Customer No.

4849

1761

: 9173 : 27752

RESPONSE TO RESTRICTION REQUIREMENT UNDER 37 CFR $\S1.142$ AMENDMENT AFTER 1^{ST} OFFICE ACTION UNDER 37 CFR $\S1.111(c)$

Mail Stop Amendment Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

INTRODUCTORY REMARKS

In response to the Office Action of April 28, 2006, please amend the aboveidentified application as follows and consider the following remarks and reconsider the application.

Please amend the above-identified application as follows:

Amendments to the Claims begin on page 2 of this paper.

Remarks begin on page 6 of this paper.